Warning: The NCBI web site requires JavaScript to function. more...
Current and new antitumor necrosis factor agents in perspective.
Maini RN.
Arthritis Res Ther. 2004;6 Suppl 2:S1-2. Epub 2004 Jun 21. Review. No abstract available.
Related citations
Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis.
Girolomoni G, Abeni D.
Arch Dermatol. 2001 Jun;137(6):784-5. No abstract available.
Switching between anti-TNFalpha agents: what is the evidence?
Combe B.
Joint Bone Spine. 2004 May;71(3):169-71. No abstract available.
TNF-alpha inhibition: the need for a tumor necrosis factor thermostat.
O'Dell JR.
Mayo Clin Proc. 2001 Jun;76(6):573-5. Review. No abstract available.
Tumor necrosis factor-alpha blockade and the risk of vasculitis.
Guillevin L, Mouthon L.
J Rheumatol. 2004 Oct;31(10):1885-7. No abstract available.
[Pharmacotherapy of rheumatoid arthritis in the era of genetically engineered biological preparations].
Nasonov EL.
Ter Arkh. 2007;79(5):5-8. Russian. No abstract available.
TNFalpha therapy in psoriatic arthritis and psoriasis.
Mease P.
Ann Rheum Dis. 2004 Jul;63(7):755-8. No abstract available.
Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases.
Feldman M, Taylor P, Paleolog E, Brennan FM, Maini RN.
Transplant Proc. 1998 Dec;30(8):4126-7. Review. No abstract available.
[1/2 The anti-TNF alpha drugs].
Medjoub M, Limat S, Woronoff-Lemsi MC.
Soins. 2007 Oct;(719):59-61. French. No abstract available.
[Adalimumab in the treatment of rheumatoid arthritis].
Bendtzen K.
Ugeskr Laeger. 2004 Jun 21;166(26-31):2552-4. Danish. No abstract available.
The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
Barton P, Jobanputra P, Wilson J, Bryan S, Burls A.
Health Technol Assess. 2004 Mar;8(11):iii, 1-91. Review.
[Risks and side effect reactions during therapy with TNF-alpha blockers. An immunologic analysis].
Berg PA.
Dtsch Med Wochenschr. 2004 Jul 23;129(30):1631-4. Review. German. No abstract available.
Optimizing the use of tumor necrosis factoralpha inhibitors in refractory uveitis.
Sebastian RT, Harding SP, Bucknall RC, Pearce IA.
Arch Ophthalmol. 2006 Oct;124(10):1505; author reply 1505-6. No abstract available.
[New treatments for rheumatoid arthritis].
Girault V, Flipo RM.
Soins. 2004 Sep;(688):37-8. French. No abstract available.
Current and future use of anti-TNF agents in the treatment of autoimmune, inflammatory disorders.
Calamia KT.
Adv Exp Med Biol. 2003;528:545-9. Review. No abstract available.
[Anti-TNF-alpha treatment and spondyloarthropathies].
Braun Y, Balbir-Gurman A.
Harefuah. 2002 Nov;141(11):965-8, 1010. Hebrew.
Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?
Khanna D, McMahon M, Furst DE.
Arthritis Rheum. 2004 Apr;50(4):1040-50. Review. No abstract available.
The role of tumor necrosis factor inhibitors in patients with RA.
Trethewey P.
JAAPA. 2002 Sep;15(9):23-4, 27, 30 passim. No abstract available.
The yin and yang of tumor necrosis factor inhibitors.
Calabrese L.
Cleve Clin J Med. 2006 Mar;73(3):251-6. Review.
Tumor necrosis factor inactivation in the management of rheumatoid arthritis.
Baumgartner SW.
South Med J. 2000 Aug;93(8):753-9. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on